Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 82 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Test Product E Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Nicotine Pouch Pharmacokinetics Abuse Liability

NCT07476144
View directory record Official record
Conditions
Smoking Behaviors
Interventions
Participants will place the pouch between their top lip and their gum for 30 minutes as per use instructions.
Drug
Lead sponsor
JT International SA
Industry
Eligibility
22 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Knoxville, Tennessee • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies

NCT03310619
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
JCAR017, Durvalumab, CC-122, Ibrutinib, CC-220, Relatlimab, Nivolumab, CC-99282
Biological · Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
9
States / cities
Duarte, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention

NCT03368456
View directory record Official record
Conditions
HIV/AIDS and Infections, Drug Abuse, Adolescent Behavior, Drug Usage
Interventions
S4E, Usual Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
14 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Ypsilanti, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Sep 5, 2026, 9:51 PM EDT
Not listed Phase 2 Interventional

A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention

NCT02174991
View directory record Official record
Conditions
Glaucoma
Interventions
Rho-Kinase Inhibitor (AR-12286)
Drug
Lead sponsor
New York Glaucoma Research Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults

NCT01458054
View directory record Official record
Conditions
Hepatitis C
Interventions
Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effects of an Eye Serum on Improving the Appearance of the Periorbital Area

NCT06143033
View directory record Official record
Conditions
Periorbital Area
Interventions
DIME Beauty Luminosity Eye Serum
Other
Lead sponsor
Dime Beauty Co.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Randomized, Controlled Agreement and Reproducibility Clinical Study

NCT05026658
View directory record Official record
Conditions
Digital Acuity Product
Interventions
Visibly Digital Acuity Product
Device
Lead sponsor
Visibly
Industry
Eligibility
22 Years to 40 Years
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Andover, Massachusetts • Shelby, North Carolina • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol

NCT05260359
View directory record Official record
Conditions
Sunburn
Interventions
6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT, Petrolatum vehicle, 0.9% Saline, Sodium Lauryl Sulfate 0.1% (SLS), Undosed patch
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSD190401: A Study to Assess Elements of Abuse Liability for Nicotine-containing Pouch Tobacco Products

NCT04372290
View directory record Official record
Conditions
Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
Interventions
Product A, Product B, Product C, Product D, Product E
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Sep 5, 2026, 9:51 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)

NCT06533280
View directory record Official record
Conditions
HIV Infections
Interventions
Part A, C and D: VH3739937 500 mg, Part A: VH3739937 100 mg, Part A and C: Placebo, Part B: Treatment A, Part B: Treatment B, Part B: Treatment C, Part B: Treatment D, Part B: Treatment E, Part D: Probe cocktail
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 21, 2025 · Synced Sep 5, 2026, 9:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

SARS-CoV-2/COVID-19 Study of Next Generation Non-Invasive Passive Detection Technologies (Level42)

NCT05765396
View directory record Official record
Conditions
COVID-19, SARS-CoV-2 Virus, COVID-19 Pneumonia, Respiratory Infection, COVID-19 ARDS, Corona Virus Infection, Influenza, RSV Infection
Interventions
imPulse™ Systems (Una and TOR) infrasound-to-ultrasound e-stethoscope
Device
Lead sponsor
The Geneva Foundation
Other
Eligibility
18 Years to 89 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Randomized Trial Comparing Misoprostol and Foley Bulb for Pregnancy Termination in the Second Trimester

NCT00324519
View directory record Official record
Conditions
Pregnancy Trimester, Second, Induced Abortion
Interventions
Foley bulb, misoprostol
Device · Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2012 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Memory Modulation in Nicotine Addiction

NCT03744559
View directory record Official record
Conditions
Nicotine Use Disorder
Interventions
Retrieval Extinction Training (RET), Control Retrieval Extinction Training (RET)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
25 Years to 65 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Testing Product Messages for Colombia

NCT04567004
View directory record Official record
Conditions
Obesity
Interventions
Control, Nutriscore Label, Adapted Peruvian Nutrient Label, Guideline Daily Amount Label
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 64 Years
Enrollment
8,071 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Sep 5, 2026, 9:51 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Cerebrovascular Reactivity Assessed With fNIRS as a Biomarker of TCVI After Acute Traumatic Brain Injury in Military

NCT04058132
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate 50Mg Tab, functional Near-infrared Spectroscopy (fNIRS), Carbon Dioxide (CO2) 5%, Neuropsychological Assessments, Gadolinium contrast infusion, Blood sample collection for research purposes, Structural brain Magnetic Resonance Imaging (MRI
Drug · Device · Other + 1 more
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 55 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSD201201: Study to Assess Elements of Abuse Liability for Electronic Nicotine Delivery System P12

NCT05210699
View directory record Official record
Conditions
Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
Interventions
Product A, Product B, Product C, Product D, Product E, Product N
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Springfield, Missouri • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phototoxicity Potential of 6% Bemotrizinol

NCT05254925
View directory record Official record
Conditions
Phototoxic Response
Interventions
Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 5, 2026, 9:51 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 5, 2026, 9:51 PM EDT
Active, not recruiting Phase 2 Interventional

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060
View directory record Official record
Conditions
Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
Interventions
Adavosertib, Afatinib, Afatinib Dimaleate, Binimetinib, Biopsy Procedure, Biospecimen Collection, Capivasertib, Computed Tomography, Copanlisib, Copanlisib Hydrochloride, Crizotinib, Cytology Specimen Collection Procedure, Dabrafenib, Dabrafenib Mesylate, Dasatinib, Defactinib, Defactinib Hydrochloride, Echocardiography Test, Erdafitinib, Fexagratinib, Ipatasertib, Laboratory Biomarker Analysis, Larotrectinib, Larotrectinib Sulfate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-beta Inhibitor GSK2636771, Radiologic Examination, Radionuclide Imaging, Relatlimab, Sapanisertib, Sunitinib Malate, Taselisib, Trametinib, Trastuzumab, Trastuzumab Emtansine, Ulixertinib, Vismodegib
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6,452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1405
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Photoallergic Potential of 6% Bemotrizinol

NCT05254912
View directory record Official record
Conditions
Photoallergic Response
Interventions
6% Bemotrizinol in sunscreen formulation, 6% Bemotrizinol in petrolatum, Vehicle
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Phase 2 Interventional Results available

Multi Immunotherapy to Test Tolerance and Xolair

NCT02626611
View directory record Official record
Conditions
Food Allergy
Interventions
Omalizumab, Food Flour Buildup
Drug
Lead sponsor
Kari Christine Nadeau
Other
Eligibility
4 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Sep 5, 2026, 9:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

CSD201202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery System P12

NCT05239884
View directory record Official record
Conditions
Smoking, Tobacco Use
Interventions
ENDS Product A with 1.5% nicotine, ENDS Product B with 1.5% nicotine, ENDS Product C with 1.5% nicotine, ENDS Product D with 1.5% nicotine, ENDS Product E with 1.5% nicotine, ENDS Product F with 1.5% nicotine, ENDS Product G with 1.5% nicotine, ENDS Product H with 1.5% nicotine
Other
Lead sponsor
RAI Services Company
Industry
Eligibility
21 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Sep 5, 2026, 9:51 PM EDT